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ABSTRACT 
Though nanotechnology which exploits the use of nanoparticles for therapeutic application 
have embarked as an emerging tool for drug delivery applications, the delivery of therapeutic 
molecules into deep ocular compartments has always been a challenging task. In this regard, 
the main objective of our current investigation was to develop and evaluate the fluocinolone 
acetonide (FA) loaded nanostructure lipid carrier (FA-NLC) in situ gel for improved ocular 
bioavailability by subconjunctival injection. FA, a corticosteroid administered for inhibiting 
the ocular inflammation either as intravitreal injection or as intravitreal implants. The FA-
NLCs were developed by using vitamin A palmitate as one of the lipid components, to get an 
additional advantage in dry eye reduction which is caused by vitamin A deficiency. FA-NLCs 
were evaluated for physicochemical characteristics (size, polydispersity index and charge), 
release and stability studies. Further, in situ gel of FA-NLC was developed using gellan gum 
and hydroxypropyl methylcellulose as gelling agents. In situ gels were characterized for 
rheological behavior, in vitro release and permeability studies using corneal and scleral 
tissues. Furthermore, the ocular pharmacokinetic studies of in situ gel were conducted in New 
Zealand albino rabbits after subconjunctival injection, and compared with control 
formulation. Differential scanning calorimetry and Fourier-Transform Infrared Spectroscopy 
(FTIR) studies revealed no interaction between the drug and lipid phase and also reduction of 
the FA crystallinity in the NLC.  FA-NLC (FN2b) showed 159.1 ± 3.8 nm of size, 0.150 ± 
0.05 of polydispersity index, -8.4 ± 0.4 of surface charge, 96.53 ± 2.4 of assay and 95.43 ± 
2.89 % as entrapment efficiency, respectively. In situ gel prepared with gellan gum showed 
excellent rheological properties, sustained drug release and significant permeability compared 
with control formulation.  FA-NLC and in situ gel was found to be stable for 30 days at room 
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and 4oC temperature. The in vivo studies revealed high drug concentration in the posterior 
section of the eye owing to high bioavailability of the drug to ocular tissues. 
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CHAPTER I 
INTRODUCTION 
 
The eye consists of complex anatomical and physiological barriers thereby making it 
a complicated organ for the delivery of therapeutic molecules across the ocular 
compartments. On this regard, lipid nanocarriers due to their diverse physical and structural 
properties help in the delivery of therapeutics across several ocular compartments. The 
complex ocular microenvironment makes eye resistant to various extraneous entities.[1] 
Cornea which forms the outermost part of the eye functions as one of the primary obstacles 
for drug permeability into ocular milieu.  Apart from the physiological structure and reduced 
permeability, poor pre-corneal volume, and residence time contribute to the diminished 
bioavailability (less than 5%) of the ocular therapeutics.[2]–[4] 
Topical delivery is the most accessed methods for the treatment of ocular diseases and 
nanotechnology, which exploits the use of nanoparticles has shown a great promise in 
transporting molecules to various tissue compartments. Delivering drug molecules via 
nanoparticulate systems like liposomes, lipid nanoparticles and nanoemulsions in the form of 
eye drops, solution or suspension, gels, lotions or ointments are the most opted ways to 
administer both hydrophilic and lipophilic drugs.[3], [5]–[8] Lipid nanoparticles are drug 
nanospheres that are shelled in biodegradable lipids. With the size ranging from 40 to 1000 
nanometers, lipid nanoparticles demonstrate a promising vehicle in drug permeability into the 
ocular tissues. Along with the nanoparticulate system, inclusion of permeability enhancer, 
2 
 
viscosity enhancer, or in situ gelling agent are considered to be the prime approach to subdue 
the low precorneal residence time.  
Vitamin A is a fat-soluble retinoid, plays a key role in the vision. An aldehyde 
derivative of vitamin A is the precursor for rhodopsin, a glycoprotein pigment component of 
rod cells presents in the retina. Deficiency in vitamin A causes ocular disorders such as dry 
eyes and keratoconjunctivitis and investigations have shown that 0.05% of vitamin A 
palmitate in the form of eye drops are efficacious for the treatment of dry eye disorder and 
this was the motivation behind the use of Vitamin A palmitate as one of the lipids to 
formulate our NLC system.[9]–[11] 
In situ gels are viscous fluids which forms pliant translucent gels by the influence of 
body pH, temperature, the presence of electrolytes or by photolytic interactions. As the 
formulation gels only after its application, in situ gel provide enhanced drug delivery similar 
to ointments or creams.[5], [12], [13] Gellan gum an anionic polysaccharide obtained from 
Pseudomonas elodea, transforms from solution to gel in the presence of cations. Tear which 
comprises of cations like sodium and potassium, facilitates the formation of double helix 
cross-linking in gellan gum, thus increasing viscosity to form the gel.[13], [14] 
Hydroxypropyl methylcellulose (HPMC) is a thermos-sensitive nonionic polysaccharide, that 
forms a transparent viscous gel in contact with the tear fluid. The gelling of the polymer is 
due to the formation of the hydrogen bonding with mucin. Therefore, addition of HPMC to 
the formulation not only provides bio-adhesion but also increases the viscosity of the 
formulation.[13], [15], [16] However, due to limitations of topical formulations like tear 
turnover, constant drug dilation and impediment endowed by the corneas results in the sub 
therapeutic ocular drug levels.  
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Subconjunctival injections are introduced into the conjunctival layer surpassing the 
lipid bulbar layer which hinders the drug penetration via the corneal route. After injecting, 
drug penetration follows the trans scleral route, thus releasing a higher amount of the drug to 
the posterior section of the eye. Due to depot formation in the conjunctival layer, this route 
delivers a greater edge for the drug concentration in the ocular tissues compared to topical 
formulations. Thus, subconjunctival injection extend to provide advantage over local drug 
delivery with limited intricacy compared to intravitreal administration.[1], [3] 
Diabetic macular edema (DME) which is one of the adverse effects of diabetes, 
induces the expansion of the fluid in the retinal section. This fluid buildup causes damage to 
the blood vessels and causes the macula to swell which initially deforms the vision and can 
eventually lead to irreversible blindness. Studies have shown the use fluocinolone acetonide 
(FA), a corticosteroid for the inhibiting the ocular inflammation caused by edema, blood 
vessel dilation, fibrin disposition, cell or capillary proliferation or by collagen accumulation. 
Currently, FA is administered as the intravitreal injection or as intravitreal implants for the 
treatment of such inflammations.[17]–[19] 
Hence, in the current study we attempted to develop a novel fluocinolone acetonide 
loaded nanostructured lipid carriers (FA-NLC) in situ gels using vitamin A palmitate. The 
physicochemical characteristics like particle size, charge, polydispersity index, assay and 
entrapment were studied. Furthermore, the gelling characteristics like viscosity with and 
without inclusion of simulated tear fluid, gelling time and gel intact time, firmness, and work 
of adhesion were investigated for in situ gel formulation. The optimized formulation was 
evaluated for the drug release, in vitro tissue permeation, tear kinetics and drug content in the 
ocular tissues by administering the in situ gel formulation via subconjunctival route in the 
New Zealand male albino rabbits compared with control formulation.  
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CHAPTER II 
METHODOLOGY 
 
Materials 
Fluocinolone acetonide, vitamin A palmitate, sesame oil, capmul PG-8, tween 80, and 
hydroxypropyl methylcellulose (HPMC) were acquired from Fischer Scientific (Hampton, 
NH, USA). Compritol 888 ATO (glyceryl behenate) was procured from Gattefossé (Paramus, 
NJ, USA). Gellan gum was purchased from MP Biomedicals, LLC (Santa Ana, CA, USA). 
Other entities required for the study like amicon ultra centrifugal filters (lined with 100 kDa 
cellulose membrane), high-performance liquid chromatography (HPLC) grade, and liquid 
chromatography mass spectroscopy (LCMS) optima grade solvents, and other analytical 
grade chemicals were obtained from Fisher Scientific (Hampton, NH, USA). 
 
Animal and animal tissues 
Complete eye globules of male albino New Zealand rabbits were acquired from Pel-
Freez Biologicals (Rogers, AR, USA). Male albino New Zealand rabbits, weighing 2 to 3 kg 
were procured from Envigo (Indianapolis, IN, USA). All the in vivo studies were carried out 
in accordance with the University of Mississippi Institutional Animal Care and Use 
committee approved protocols (Protocol # 17-018). 
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Preparation of FA-NLC and in situ gels 
Selection of lipids 
Lipids were screened on the basis of the relative drug affinity towards them. About 5 
mg of drug was added to 10 mL of water in glass vials. To these approx., 1 g of lipid was 
added, and the vials were kept in shaking water bath at 75oC for 24 h. The solubility of the 
drug was later measured by precipitating out the lipid in methanol, followed by centrifugation 
for 15 minutes (AccuSpin 17R centrifuge, Fisher Scientific, USA) at 13,000 rpm and 
analyzing the drug in methanol using HPLC method.[20] 
 
Selection of surfactants 
Drug solubility was carried out in the categories of surfactants based on their HLB 
values. For this purpose, about 5mg of FA was added to 10 mL of different 5% surfactant 
solutions and was kept at 34oC with continuous shaking. Later the samples were centrifuged 
with AccuSpin 17R centrifuge (Fisher Scientific, USA) at 13,000 rpm for 15 min and the 
supernatant was diluted with methanol and analyzed using HPLC method. The surfactant 
screening was performed on the basis of the solubility of the drug on various surfactants.[20] 
 
Preparation of FA-NLC 
Hot melt homogenization coupled with probe sonication technique was utilized to 
prepare FA-NLCs.[21] The proportion of the drug and all the excipients for different trials 
were provided in Table 1. The quantity of lipids and surfactants for the formulation were 
determined based on different ratios taking one factor at a time. The lipid phase which 
constitutes of Compritol 888 ATO and vitamin A palmitate as solid lipids and sesame oil as 
liquid lipid, were melted together at 80oC. FA was added to this liquefied lipid with steady 
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magnetic stirring until a homogenous mixture was obtained. Later, capmul PG-8 was added 
to this homogenous mixture. In a separate vial, aqueous phase comprising of deionized water 
and tween 80 was heated to 80oC. On attaining the constant temperature, the aqueous phase 
was added to the apparent lipid with constant stirring to get pre-emulsion. This mixture was 
homogenized at high speed with T25 digital Ultra-Turrax for 5 min at 12000 rpm. The 
homogenized mixture was then imposed to probe sonicator for 5 min at 40% amplitude with 
15 sec pulse and 15 sec resting time to get desired nanoparticles. The pH of the formulations 
was analyzed using pH meter (Mettler Toledo, USA). 
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Table 1: Composition of fluocinolone acetonide loaded nanostructure lipid carriers 
F and N indicate fluocinolone acetonide and NLC respectively. Each formulation contains 10 
mg of drug and were prepared for 10 mL. 
 
Fluocinolone acetonide in situ gels were prepared in the similar fashion as specified 
above (using optimized FA-NLC formulation). The gelling agents, gellan gum, and HPMC 
were added to aqueous phase and homogenizing the two phases.  
 
HPLC Chromatographic conditions 
The drug content in the samples was analyzed by means of High-Performance Liquid 
Chromatography (HPLC) using Waters 717 plus autosampler, 600 Waters controller pump, 
Waters 2487 ultraviolet (UV) dual absorbance detector and Agilent 3395 integrator. The 
column used for analysis was C18 Luna ® 4.6mm x 250 mm and mobile phase comprised of 
acetonitrile (ACN), water and tetrahydrofuran (THF) in the ratio of 77:13:10, respectively. 
The detection wavelength (λmax) was set at 238 nm with the flow rate of mobile phase at 0.8 
mL/min. All the samples were analyzed in triplicates for each study.[22] 
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Characterization of NLC 
Measurement of particle size, polydispersity index (PDI) and zeta potential (ZP)  
All the prepared NLC formulations were evaluated for particle size, zeta potential 
(ZP) and PDI in triplicate, using a Zetasizer Nano ZS Zen3600 (Malvern Instruments, Inc., 
MA, USA) by photon correlation spectroscopy at 25°C and with 173° backscatter detection 
in clear, disposable folded capillary cells. The results for the particle size and PDI were 
acquired based on volume displacement at 633 nm using a helium-neon laser. The samples 
were diluted with doubled distilled 0.2µ filtered water in the ratio of 1:500. 
Assay and entrapment efficiency 
The assay of the FA-NLC and in situ formulation was quantified by lipid precipitation 
method. About 100 µL of the formulation was added to 900 µL of mobile phase (77:13:10 of 
ACN: Water: THF) and vortexed to precipitate out the lipid. Later, the samples were 
centrifuged for 15 min at 13,000 rpm and the supernatant was analyzed for the drug content 
using HPLC method. 
Entrapment efficiency (EE) of the FA-NLC formulations was determined by 
analyzing the free drug in the filtrate collected after centrifuging the formulation through 
amicon ultra centrifugal filters for 15 min at 5000 rpm. Drug analysis was done by HPLC 
method as discussed earlier. The entrapment efficiency (%) of FA was calculated using the 
equation mentioned below. 
%𝑬𝑬 =
(𝑾𝒇 − 𝑾𝒊) ∗ 𝟏𝟎𝟎
𝑾𝒊
 
Where, Wi is the theoretical weight of the drug in formulation and  
 Wf is the total free drug in the filtrate. 
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Differential scanning calorimetry (DSC) 
The purity and interaction of the drug with other lipid components was determined by 
subjecting to DSC analysis. DSC of pure FA and the lipid phase of the formulation including 
drug were obtained by DSC 250 (TA instruments, USA). Approx. 5 mg of solid samples were 
hermetically sealed in the T0 aluminium pans and scanned from 0 to 320 °C with the heating 
rate of 10°C/min with constant nitrogen purging. 
 
Fourier transform infrared spectroscopy (FTIR) 
The FT-IR spectra of pure drug (FA), excipients and the physical mixture of the lipid 
phase was evaluated utilizing Cary 660 series FTIR (Agilent Technologies, Place, Country) 
and MIRacle ATR (attenuated total reflectance) systems to investigate the interactions of the 
excipient on the drug. 
 
Characterization of FA-NLC in situ gel 
Rheological and in vitro gelling characteristics 
In situ gelling agents in the formulation includes gellan gum alone and combination of 
gellan gum with HPMC. The viscosity of the FA-NLC formulations and in situ gels was 
determined using Brookfield cone and plate viscometer (LV-DV-II+ Pro Viscometer, 
Middleboro, USA). The distance between the cone spindle and sampler cup was maintained 
to the minimum and the temperature of the system was set to 34 ± 0.2 °C. Later 
approximately 500 µL of sample was added to the cup and viscosity of the sample was 
evaluated at different shear stress using CPE 52 spindle. The viscosity of the gel formulations 
was also determined with simulated tear fluid (STF) with the ratio of 50:7 of the formulation 
to STF so as to mimic the viscosity of the formulation after application into the eye. 
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Simulated tear fluid with pH of 7.0 ± 0.2 consists 0.678 g of NaCl, 0.0084 g of CaCl2·2H2O, 
0.138 g of KCl, and 0.218 g of NaHCO3 in 100 mL of deionized water.[23] The viscosities 
were registered from the Rheocalc software. 
Gelling formation and gel residence time 
Gel formation time of the in situ formulation was determined by placing approx. 50 
µL of the formulation in a vial containing 10 mL of freshly prepared STF and visibly 
checking the time taken by the formulation to gel in the fluid. Gel residence time was the 
total time of the formulation resides intact within the STF. Approximately 50 µL the 
formulation was added to the 10 mL of freshly prepared STF and the vial was kept at 34 ± 
0.2°C with constant stirring. Time was recorded when the gel was breaking down or no 
longer remained intact. 
 
Gel firmness and adhesion 
TA XT2i texture analyzer (Texture Technologies Corp. NY. USA) was utilized to 
measure the gel firmness and work of adhesion for the optimized in situ gel formulation. At 
the room temperature, the gel formulation was mixed with freshly prepared STF in ratio 50:7 
was held on soft matter holder (TA-275). The measurement was done by compression mode 
where 1-inch cylinder acrylic probe was embedded to the distance of 1 mm into the gel 
formed with the speed of 0.5 mm/sec and 5 g of the triggering force. 
 
Measurement of turbidimetry  
FA-NLCs and in situ gels were examined for the percent transmittance (%T) at the 
wavelength (λmax) of 520 nm using UV Genesys 6 (Thermo Fischer Scientific, USA) to 
check visible transparency.[13] The turbidity of the formulations was measured over a period 
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of 6 h after placing the formulation in STF in the ratio of 50:7 of formulation to tear fluid. 
%T was calculated using the following formula: 
𝑨 = 𝟐 − 𝒍𝒐𝒈 (%𝑻) 
Where, A is absorbance of the sample when compared with deionized water. 
 
In vitro release study 
The release kinetics for the FA-NLCs and in situ gels were evaluated by adding 200 
µL of the formulation to 10 mL of isotonic phosphate buffer saline (IPBS) (pH 7.4) with 5% 
methyl β cyclodextrin. The temperature of the vials was maintained 34 ± 0.2 °C with 
continuous magnetic stirring for 4 h. Approx. 1 mL of the aliquot was withdrawn at 
predetermined time points and was replaced with equal volume receiver medium. The 
samples were analyzed for the amount of drug by HPLC method. 
 
Stability studies 
The formulations were placed at 4oC and 25oC for weeks to assess their stability 
during storage. Samples from the formulations were withdrawn at predetermined time point 
and were evaluated for their particle size, PDI, surface charge, EE and assay as specified 
earlier. About, 3 mL of the formulations, both NLCs and in situ gels were taken in the glass 
vials and placed in the autoclave (AMSCO Scientific Model SI-120, USA) for pressure 
controlled sterilization at 121°C for the time period of 60 min at 15 psi pressure. The 
formulations were examined for their physical characteristics compared to the formulation of 
before sterilization. 
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In vitro permeation studies 
Post-development of the FA-NLC and corresponding in situ gel, the formulations 
were examined for their permeation release in the ocular tissues. The in vitro permeation 
studies were carried out on corneal and scleral tissues. Whole rabbit eyes were bought 
overnight from Pel-Freez Biologicals in Hanks balanced salt solution. The permeation study 
was performed immediately after receiving the eyes. The tissues were separated and were 
washed within ice-cold Dulbecco’s phosphate buffer saline (DPBS) solution with pH 7.4 and 
later were mounted in between the donor and receiver on valia-chein diffusion cells 
(PermeGear, Inc®, USA) with the epithelial tissue section towards the donor compartment of 
the cell. 
The receiver medium constituted of balanced salt solution (BSS) (pH 7.4) with 5% 
methyl-β- cyclodextrin. The temperature of the cells was maintained at 34 ± 0.2°C and the 
receiver was under continuous magnetic stirring throughout the experiment of 3 h. Approx. 
200 µL of the formulation along with 50 µL of DPBS was added to the donor compartment 
for the formation of sol-gel. The control used for the study was fluocinolone acetonide (0.1%) 
suspended in deionized water containing gellan gum (0.3%) and HPMC (0.5%). About 600 
µL of aliquots were pipetted out of the receiver cells and was replaced with equal volume 
receiver medium. The samples were analyzed for the concentration of drug by HPLC method. 
From the concentration; cumulative concentration, steady-state flux, and tissue 
permeability were estimated. The equations for calculating cumulative concentration was  
𝑴𝒏 =  𝑽𝒓𝑪𝒓(𝒏) +  ∑ 𝑽𝒔(𝒙−𝟏)𝑪𝒓(𝒙−𝟏)
𝒙=𝒏
𝒙=𝟏
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Where, n is the number of sampling time point; Vr (mL) is the volume in the receiver cell and 
VS (mL) is the volume of the sample collected on time points. Cr(n) (µg/mL) is the drug 
concentration in the receiver chamber medium at the nth time point. 
Flux is the rate of drug permeated through the tissue membrane per area of the tissue. 
The calculation of the flux was determined from the slope of the cumulative drug permeation 
versus time plot. The equation for calculating flux was: 
𝑭𝒍𝒖𝒙(𝑱) = (𝒅𝑴/𝒅𝒕)/𝑨 
Where, M is the cumulative amount of drug transported and A is the surface area of the tissue 
(0.636 cm2) 
The equation to determine the tissue permeability was: 
𝑷𝒆𝒓𝒎𝒆𝒂𝒃𝒊𝒍𝒊𝒕𝒚 (𝑷𝒂𝒑𝒑) =
𝑺𝒕𝒆𝒂𝒅𝒚 𝒔𝒕𝒂𝒕𝒆 𝒇𝒍𝒖𝒙 (𝑱)
𝑫𝒐𝒏𝒐𝒓 𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏
 
 
In vivo tear kinetics and distribution studies 
In vivo studies were conducted in New Zealand male albino rabbits. Before the study, 
the animals were kept for acclimatization up to 7 days with absolute access to food and water. 
The formulations used for drug distribution studies were in situ gel and control, which were 
administered via topical and subconjunctival route. The animals were divided into 4 groups 
and the formulations were administered to the left eye of each animal and keeping the other 
eye untreated. The study was conducted for 3 h on the animals treated with topical drops and 
6 h for animals treated with subconjunctival injection. Topically, 50 µL of the formulations 
were instilled into the cul-de-sac of left eye while for the subconjunctival route, 50 µL of the 
formulations were injected accurately into the conjunctival membrane with tuberculin syringe 
and 27-gauge needle. Around 15 minutes prior to injection, the rabbits were anaesthetized 
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with combination of ketamine and xylazine via intramuscular route. Approximately 5 µL of 
tear fluid was pipetted out from the cul-de-sac of the test eyes using micro pipette at every 30 
minutes for animals treated topically and at 60 minutes for animals treated with 
subconjunctival injections. Approximately 10 minutes prior to the end time of the study, all 
the animals were anaesthetized with same combination and were euthanized with 
pentobarbital overdose via marginal ear vein. Both the test and untreated eyes were excised, 
and washed with ice cold IPBS solution. The tissues were carefully isolated and were stored 
at -80 °C until the drug extraction and quantification. 
 
 
Extraction procedure of drug from ocular tissues 
Drug extraction from the ocular tissues were carried out by protein precipitation 
technique. Analysis for the drug content was performed on plasma, aqueous humor (AH), 
vitreous humor (VH), cornea, iris-ciliary (IC), retinal choroid (RC), sclera and conjunctiva. 
Individual weights of all the solid tissues were measured and later each tissues were minced 
into small fragments and kept in separate vials. To all the tissues, the relevant amount of 
triamcinolone acetonide with the concentration of 1 µg/mL (as internal standard) was added. 
The vials were then vortexed thrice for 30 seconds each with the gap of 10 minutes between 
each vortexing. Later, 1000 µL ice-cold methanol with 0.1% formic acid was added to each 
vial and the process of vortexing was repeated. The samples were then centrifuged for 15 
minutes at 13,000 rpm to separate out the precipitate, and the supernatant was then collected, 
diluted if required and spiked in UPLC-triple quadrupole (TQ)-MS system for analysing the 
concentration.  
For liquid samples, 100 µL of plasma, 100 µL of AH and 500 µL of VH samples were 
collected and similar extraction procedure was followed with 100 µL, 100 µL and 500 µL of 
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ice-cold methanol was utilized for plasma, AH and VH respectively. After centrifuging for 15 
minutes the samples were analyzed in UPLC-triple quadrupole (TQ)-MS system. The drug 
content from the tear samples collected during the in vivo study was extracted using ice cold 
methanol and analyzed in the same system. 
For analysis of FA, Ultra-Performance Liquid Chromatography system coupled with a 
triple quadrupole mass spectrometer (UPLC-TQ-MS) (Waters, USA), was utilized. The 
quantification peaks of both the drug and the internal standard were obtained on the basis of 
specific mass to charge (m/z) values of same.[24] 1 µL of the sample was eluted through 
BEH C18 1.7 µm Acquity UPLC® column and separated using isocratic mode of ACN with 
0.1% formic acid and water with 0.1% formic acid 1 µL of the sample was eluted at the ratio 
of 98:2 respectively. The extraction efficiency, limit of detection and limit of quantification 
of the drug was analyzed prior to drug concentration analysis. 
For tear kinetics, from the concentration, the slope for the graph of time v/s 
concentration was calculated which was further used to calculate time at which the 
concentration of drug is half the initial concentration (t1/2) using the formula 
𝒕𝟏/𝟐 =
𝟎. 𝟔𝟗𝟑
𝒔𝒍𝒐𝒑𝒆 ∗ −𝟐. 𝟑𝟎𝟑
 
 
Area under curve (AUC) for the plot was calculated using the formula 
𝑨𝑼𝑪 = ∑[
(𝑪𝟏 + 𝑪𝟐)
𝟐
∗ (𝒕𝟐 − 𝒕𝟏)] 
Where C1 and C2 are drug concentration in tear at time t1 and t2 respectively. 
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Statistical analysis 
Results were presented in their mean values ± standard deviation (SD). Statistical 
analysis for in vitro permeation study and in vivo drug distribution study in ocular tissues was 
done by One-way ANOVA (analysis of variance test) with Tukey’s post hoc test (R Studio 
software, USA). The confidence interval set for the statistical analysis was 95% and hence 
the p-value for the significant difference was less than 0.05 (p < 0.05). 
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CHAPTER III 
RESULTS AND DISCUSSION 
 
Formulation development and optimization of FA-NLCs 
Fluocinolone acetonide NLCs were formulated by hot homogenization along with 
probe sonication. For formulating the NLCs, varied ratios of lipid to surfactant, and solid 
lipid to liquid lipid and primary surfactant to secondary surfactants were considered. 
Optimization of the formulation was determined based on the effect of these ratios on particle 
size, ZP and drug content. All the ingredients utilized in the formulations are naturally 
occurring and thus are biodegradable and the extent to which they were used in the 
formulations were below the safety limits mentioned by FDA inactive ingredient limit.[25] 
Selection of lipids whether solid or liquid and surfactant was based on the partitioning 
behavior of the drug in respective component. Better the affinity, higher quantity of the drug 
could be withholding within the formulation, thereby increasing both the percent drug content 
and entrapped into the formulation. The selection of the lipid study shows that the drug had a 
higher solubility towards didodecyldimethylammonium bromide, lauric acid, and compritol 
888 ATO (Figure 1). Since compritol 888 ATO had shown the highest solubility i.e. 4.37 
mg/g, hence, compritol 888 ATO was preferred over other as solid lipid for the development 
of FA-NLC formulation.[20] Retiene, an aldehyde derivative of vitamin A has a fundamental 
effect on the vision. Inadequacy in the content for vitamin A in the retina may progressively 
lead to night blindness. Also, due to its low melting point (<30oC), vitamin A palmitate 
provides more flexibility and imperfect crystallinity to the NLC structure, thus decreasing the 
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drug leaching and also act as a permeation enhancer. Hence, vitamin A palmitate was 
selected as solid lipid in combination with compritol 888 ATO for the formulation. Similarly, 
in case of liquid lipids FA showed a higher affinity towards isopropyl myristate, miglyol and 
sesame oil (Figure 1). However, because of its high physical compatibility and also due to its 
natural origin, sesame oil was chosen over others as the liquid lipid component for the 
preparation of FA-NLCs. The total lipid content in the formulation ranged from 1 to 2% 
where higher lipid content contributes to high drug solubility. 
Further, the selection of the surfactants was done based on the highest solubility of 
FA in the surfactant solution. In general, a combination of the surfactants with the HLB range 
from 4 to 7 (W/O emulsifiers) and with the HLB range from 8 to 18 (O/W emulsifiers) was 
adopted for the preparation of NLCs were showed better stability.[26]  From the solubility 
results, a higher amount of FA solubility was observed with capmul PG 8, capryol 90, tween 
80 and propylene glycol (Figure 1). Similarly, O/W surfactant that shows low solubility was 
preferred as secondary surfactant for the formulation preparation. From the figure 1 we can 
see that tween 80 and poly ethylene glycol 4000 had lowest solubility from all O/W 
surfactants. Therefore, on the basis of their  physical compatibility and formulation stability, 
capmul PG 8 and tween 80 were selected as W/O and O/W emulsifiers for the preparation of 
FA-NLC respectively.[12] 
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Figure 1: Solubility of drug in various lipids and surfactants (mean±SD, n=3) 
 
 
The proportion of the excipients utilized to formulate FA-NLCs were mentioned in 
Table 1. For the development and optimization of the NLCs, various variables along with 
their impact on characteristic features and stability of NLC were taken into consideration.[20] 
These variables include different ratios of lipid to surfactant, solid to liquid lipid as well as 
the ratio of W/O and O/W emulsifiers. Percent FA entrapped in all the formulation was in the 
ranging of 60 to 97, with size and PDI in the range of approx. 160 to 270 nm and 0.15 to 
0.52, respectively. The EE of the drug in all the formulations was greater than 91%, while the 
charge for the most of the formulations falls in the range of -8 to -10 mV (Table 2). 
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Table 2: Effect of lipid to surfactant and solid to liquid lipid ratio on size, PDI, ZP, EE and 
assay of fluocinolone acetonide NLC formulations (mean±SD, n=3) 
 
 
In the early stages of formulation development, the ratio of lipid to surfactant and 
solid to liquid lipid was premeditated keeping the surfactant concentration constant and their 
corresponding effect on particle size, PDI, and the assay were studied (Table 2). If the lipid to 
surfactant ratio was 1:1, the particle size and PDI of the nanoparticles was found to be 
considerably low in the range of 160 to 210 nm and responsible for better NLC formulation. 
These results were observed in the formulations FN1, FN2, and FN3. However, increase in 
the lipid content compared to surfactant concentration i.e., the ratio of 2:1 and 2:1.5, gave a 
good particle size but distribution of the particles was more. These results exhibit that if the 
amount of surfactant, when compared to lipid was less, distribution of the particles in the 
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formulation increases. Similarly, the overall percent drug content of the FA-NLC scales down 
to less than 90%, when the difference between the lipid and surfactant was higher. These 
results were observed in FN4, FN5, FN7, FN8 and FN9 NLC formulations. The overall 
reduction in PDI and drug content could be due to the measure of surfactant which was 
adequate enough to form nanoparticulate emulsion, but inadequate to stabilize the same. This 
can also be attributed to the surface charge of the formulations. Higher the difference 
between lipids and surfactant features the surface charge more towards 0 which in turn leads 
to more of instability. The ratio of solid to liquid lipid was determined on the basis of higher 
drug solubility in lipid along with the suitable blend of solid and semi solid consistency of the 
phase at room temperature. Since the solubility of FA was observed higher for solid lipids, a 
higher proportion of solid lipid was favored in total lipid content. The preferable ratio 
selected for formulation trials were from 70:30 to 90:10.[27] The evaluation results with 
respect to different ratios of solid to liquid lipid ratio were mentioned in Table 2. It can be 
inferred that relatively lower amount of sesame oil in the total lipid combination gave lower 
assay values and when the ratio was other than 80:20, the PDI of the formulation was also 
high. Therefore, in accordance with above assumption, the ratio of lipid to surfactant and 
solid to liquid lipid was set as 1:1 and 80:20 respectively. 
 
Table 3: Effect of O/W to W/O surfactant ratio on size, PDI, ZP, EE and assay of 
fluocinolone acetonide NLC formulations (mean±SD, n=3) 
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Both lipid to surfactant (1:1) and solid to liquid lipid (8:2) ratio are constant for all the 
formulations. Formulation FN2b is same as formulation FN2 from table 2. Change in name of 
formulation was done to have different representation in accordance with table 3. 
 
After finalizing the quantity of lipids and total surfactant, formulation FN2 was 
further evaluated for its characteristic features with various fraction of O/W and W/O 
emulsifiers. From the Table 3, it can be presumed that size and PDI of nanoparticles with 1:1 
ratio for capmul PG 8 and tween 80 was high and % entrapment was low compared to other 
ratios. On the other hand, when the ratio of two surfactants was 1:3, the polydispersity of 
formulation was high. When the ratio of O/W and W/O emulsifiers was taken as 1:2, the 
average size, polydispersity index and assay of FA NLC was found to be 159.1 ± 3.8 nm, 
0.150 ± 0.05, -8.4 ± 0.4, 96.53 ± 2.4 % and 95.43 ± 2.89 % respectively.  The combination of 
capmul PG 8 and tween 80 surfactants i.e. with the HLB value 6 and 15 exhibited excellent 
NLC formulation possibly because capmul PG 8 (W/O surfactant) forms a layer around the 
formed particles and tween 80 (O/W surfactant) stabilizes the formed particles with 
surrounding aqueous phase by lowering the surface tension.[26] Therefore, formulation FN2b 
was considered as optimized and selected for the preparation of in situ gel formulation. 
 
Formulation development and optimization of FA-NLC in situ gels 
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One of the critical quality attributes for in situ ophthalmic gel formulation is its flow 
properties, as it helps to administer the formulation without any complication while 
instillation into the ocular milieu. FA in situ gels was prepared by using various concentration 
of gellan gum alone and combination with HPMC to provide ideal gelation along with 
formulation’s rheological characteristic. Gellan gum is an anionic polysaccharide, which 
forms a clear gel due to the presence of mono or divalent cations. An ideal viscosity for 
ophthalmic solution ranges from 25-50 cP.[28] The concentration of gellan gum used and 
their corresponding results on viscosity and other rheological characteristics of in situ gel 
presented in Table 4. Since the viscosity of the formulation FN2G3 (0.3% of gellan gum) was 
40.3 ± 1.8, gels immediately when in contact with STF and reside as gel for up to 6 h. Hence, 
0.3% of gellan gum was selected as the optimum concentration for in situ gel formulation and 
was used for the further analysis. 
Methocel E5 is a neutral polymer which forms viscous solution by hydration of 
hydrogen bonding in the polymer chains. Methocel E5 is a low molecular weight, 
temperature sensitive polymer and increases the viscosity at around 35°C. The rheological 
characteristic results of the formulation with varied concentrations of HPMC was presented 
in Table 4. The viscosity of the formulation has been increased with increased concentration 
of HPMC. The viscosity of the formulation holds in the ideal range for ophthalmic solution 
even after addition of 0.5% concentration of HPMC to FN2G3 formulation owing to form 
ideal in situ gelling system with higher viscosity value after addition to STF.[15], [16] 
One of the major fall back for ophthalmic formulation is low inhabitancy in the cul de 
sac. The gelling time of the formulation was determined so as to compute the time required 
by in situ gelling formulation to form gel on contact with tear fluid. All the concentration of 
gellan gum formulations (with and without HMPC) were observed to gel as soon as they 
were added to the simulated fluid. The results of gelling time and gel residence time of in situ 
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gels were specified in the Table 4. Firmness of the formulation was tested to analyze the 
resistance of the gel to the external deformation and work of adhesion for the formulations 
was done to analyze the adhesiveness of the gels when in contact with the tear fluid.[14], [29] 
Firmness and work of adhesion for the formulation with 0.3% and 0.5% of gellan gum and 
HPMC respectively with respect to time was showed in Figure 2. From the results, the values 
for firmness and work of adhesion do not show significant variation even after 6 h, 
suggesting the intactness of the gel for extended period of time (6 h). Therefore, in 
accordance with the results and inference discussed in above sections, formulation FN2b and 
FN2GH05 were considered as optimized FA-NLC and in situ gel formulation and were 
chosen for the further studies. 
 
Table 4: Rheological evaluation of fluocinolone acetonide NLC in situ gel formulations 
(mean±SD, n=3) 
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G and H indicates gellan gum and HPMC containing in situ gels respectively. 
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Figure 2: Firmness (A) and work of adhesion (B) for in situ gels with respect to time 
(mean±SD, n=3) 
 
Stability studies of FA-NLC  
The stability of FA-NLC formulation upon storage was evaluated by studying their physical 
appearance and characteristics once a week for up to 4 weeks. Until 30 days, the formulation 
did not show any sign of physical separation or breaking. The results for particle size, PDI, 
assay and EE were shown in Figure 3. Further, the formulation was also tested for 
postproduction sterility by moist heat sterilization. As per stability studies, the physical 
aspects of the formulation did not exhibit any breaking or phase separation. It can be 
determined that there was no significant change in any of the parameters tested. This could be 
stating that the formulation was still intact after sterilization and also post 28 days of storage 
without any phase separation or particle aggregation or drug oozing out of NLC gel. 
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Figure 3: Stability studies of optimized FA-NLC and in situ gel at 4°C and 25 °C for 28 
days, by autoclave on size and PDI (A), assay and entrapment efficiency (B) (mean±SD, n=3) 
 
 
Compatibility studies - DSC and FTIR 
The DSC thermograms of the FA and the physical mixture of the drug with lipid 
phase is portrayed in Figure 4. The melting point of pure FA was found to be at around 270oC 
as shown by evolution of a sharp endothermic peak corresponding to its reported melting 
point. In case of lipid phase (including drug) DSC thermogram, there was a slight concavity 
at around 55 to 60oC of compritol 888 ATO followed by constant heat flow up to 300oC. 
This verifies the complete solubility and/or conversion of the drug in to amorphous form in 
the lipid phase, as no separate endothermic peak was observed for the drug in NLC-lipid 
phase thermogram. 
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Figure 4: DSC thermograms of drug and NLC-Lipid phase 
 
 
FTIR spectroscopy was performed for the drug and NLC to determine the potential 
interaction between FA and lipid matrix throughout the formulation procedure. The FTIR 
spectra for drug, lipid excipients and FA-NLC formulation is showed in Figure 5. For all the 
spectras of lipid excipients and drug, the major bands were observed at around 1640 cm- 
assigned to C=C, and around band 1728 cm- was assigned to C=O group. The bands from 
2995 to 2952 cm- were assigned to C-H group. The NLC spectra exhibited the peak at 2916 
cm- for C-H group and 1665 cm- for C=C. There was a slight spectral variation for NLC, 
which might be due to overlapping of the similar functional group for various components. 
However, there was no change in the band peaks for pure excipients and peaks in the NLC 
spectra even in the presence of FA, indicating no substantial interaction between the drug and 
excipients. 
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Figure 5: FTIR spectra of the drug and NLC-Lipid phase and excipients 
 
 
In vitro release study  
Since the saturation solubility of FA was found to be maximum in BSS (pH 7.4) with 
5% methyl- β- cyclodextrin. BSS solution was preferred as the receiver medium for in vitro 
release and in vitro permeation studies.[30] The in vitro release profile of FA from control, 
NLC, and in situ gel are presented in Figure 6. The cumulative release of the drug from 
control, NLC, and in situ gel was found to be 102.34 ± 8.08, 46.62 ± 4.65, and 35.44 ± 4.39 
% respectively within the period of 4 h. It could be due to the slow diffusion release from the 
shell layer of lipid nanoparticles during the period of 4 h. 
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Figure 6: In vitro drug release profiles of fluocinolone acetonide from control gel, FA-NLC 
and in situ gel (mean±SD, n=3) 
 
 
Turbidimetry measurement 
The percent transmittance (%T), provide the extent of turbidity which could be the 
extent of light obstruction during post injecting the formulation into the eye.[13] The 
transmittance results for formulations over the period of 6 h are mentioned in Table 5. The % 
transmittance for the in situ gel formulation was low due to cross-link formed by the gelling 
agent in contact with STF. This indicates that, the gel link breaks with time with increase in 
transmittance and thus releasing the formulation at the controlled rate. 
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Table 5: Transmittance (%) of fluocinolone acetonide NLC and in situ gel formulation 
(mean±SD, n=3) 
Formulation 
Transmittance (%) 
0 h 3 h 6 h 
FA-NLC 35.08 ± 2.18 35.73 ± 3.21 38.11 ± 2.54 
In situ gel 3.35 ± 0.71 15.35 ± 1.84 36.48 ± 4.47 
 
 
In vitro permeability studies 
The permeability of FA-NLC, in situ gel and control formulation were performed in 
corneal and scleral tissues and the results presented in Figure 7. The tissue permeability of 
PA form control, FA-NLC and in situ gel formulations were found to be 1.52 ± 0.2 x10-5 
cm/s, 5.66 ± 0.18 x10-5 cm/s and 2.41 ± 0.08 x10-5 cm/s, respectively from corneal tissue 
and 2.32 ± 0.14 x10-5 cm/s, 6.34 ± 0.1x10-5 cm/s, and 3.83 ± 0.21x10-5 cm/s, respectively 
from scleral tissue.  The flux values for control, FA-NLC and in situ gel formulations were 
found to be 0.18 ± 0.02 μg/min/cm2, 0.68 ± 0.08 μg/min/cm2 and 0.29 ± 0.01 μg/min/cm2, 
respectively for corneal tissue and 0.28 ± 0.02 μg/min/cm2, 0.76 ± 0.03 μg/min/cm2, and 
0.46 ± 0.04 μg/min/cm2, respectively for scleral tissue. A significant increment in the tissue 
permeability and flux was observed form both FA-NLC and in situ gel formulation compared 
to the control formulation. The enhancement in permeability of FA form NLC and in situ gel 
formulations in comparison to control might be due to lipophilicity of the formulation and 
which imparts higher penetration through the tissues. Further, the lower flux of the drug from 
in situ gel formulation compared to NLC formulation indicates the slow release of the drug 
from in situ gel owing for controlled release. Furthermore, the drug permeability was higher 
through the sclera compared to cornea, suggesting that non-corneal route may show better 
drug penetration compared to the corneal route[1], [7], [12]. 
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* indicates the data for formulations is significant compared to control 
Figure 7: In vitro permeability studies of fluocinolone acetonide from control suspension, 
FA-NLC and in situ gel through ocular tissues (mean±SD, n=3) 
 
In vivo tear kinetics and distribution study 
In vivo distribution studies of FA from control and FA-NLC in situ gel formulations 
was carried out in New Zealand albino rabbits treated by topical and subconjunctival 
administration. The drug content was observed in rabbits treated with topical and 
subconjunctival injection after 3h and 6h, respectively. The drug contents were estimated in 
the tear after every 30 min for topically and every 60 min for subconjunctivally administered 
formulations and were presented in the Table 6. From the results, it was observed that the 
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highest concentration of the drug was observed at first 30 min (3.37 ± 2.10 µg/mL) with 
topical and first 60 min (3.10 ± 0.20 µg/mL) with subconjunctivally administered 
formulation. The half-life of FA from in situ formulation was found to be 3.22 h and 1.64 h 
by subconjunctival injection and topical formulation. In case of ocular bioavailability, about 
2.32 and 2.29-folds enhancement was observed with subconjunctival and topical 
administration when compared with control gel. This could be due to the diffusion release of 
the drug from the lipid nanoparticles into the tear and then its permeation through the cornea. 
As evident from the Table 5, the rate of drug expulsion from NLC in situ gel was predicted to 
be a sustained release, as the concentration of the drug in tear decreased gradually compared 
to the control formulation. Thus, the tear kinetic analysis clearly explains the release pattern 
of the drug for different formulations.[31] 
 
Table 6: In vivo tear kinetics for fluocinolone acetonide from in situ gel formulation and 
control in New Zealand albino rabbits (mean±SD, n=3). 
For subconjunctival formulations 0, 1, 2, 3, 4, 5 and 6 represents 0 min, 60 min, 120 min, 180 
min, 240 min, 300 min and 360 min respectively and for topical formulations 0, 1, 2, 3, 4, 5 
and 6 represents 0 min, 30 min, 60 min, 90 min, 120 min, 150 min and 180 min respectively 
34 
 
 
The concentration levels of FA from in situ gel and control formulation in aqueous 
humor (AH), vitreous humor (VH), cornea, iris ciliary (IC), retinal choroid (RC) and scleral 
tissues after topical and subconjunctival administration are showed in Table 7 and Figure 8. 
From the results, the drug concentration in the aqueous humor and vitreous humor were 
determined to be 0.016 ± 0.00 µg/mL and 0.005 ± 0.01 µg/mL for control formulation and 
0.021 ± 0.01 µg/mL and 0.008 ± 0.01 µg/mL respectively for in situ gel by topical 
administration (Figure 8a). The high concentration of drug was observed in cornea and IC 
after 3 h post administration and thereby explaining the effectiveness of the in situ gel system 
in ocular tissues. Additionally, significantly high concentration of the drug was observed in 
scleral and RC tissues (p value < 0.05), suggesting high drug permeability from our novel in 
situ gel system in the posterior ocular compartment. Hence, enhancing the release kinetics of 
the drug in ocular tissue.[5], [32] 
 
Table 7: In vivo fluocinolone acetonide distribution in ocular tissues from in situ gel 
formulation in New Zealand albino rabbits (mean±SD, n=3). 
* indicates the value is statistically significant compared to control for same route. 
35 
 
 
* indicates the value is statistically significant compared to control for same route. 
Figure 8: in vivo fluocinolone acetonide distribution in ocular tissues (A) Topical 
formulation (B) Subconjunctival formulation (mean±SD, n=3). 
 
 
For subconjunctival injection, considerably high concentration of the drug was 
observed in sclera and RC when treated with in situ gel compared to control formulation. The 
concentration of drug in AH, cornea, IC, sclera and RC were 0.021 ± 0.01 µg/mL, 4.87 ± 
3.64 µg/g, 0.51 ± 0.03 µg/g, 43.81 ± 27.71 µg/g, 12.44 ± 4.60 µg/g and 0.003 ± 0.00 µg/mL, 
1.42 ± 0.15 µg/g, 0.28 ± 0.13 µg/g, 11.12 ± 0.65 µg/g and 5.24 ± 3.78 µg/g, respectively from 
in situ gel and control gel, which was significantly higher. Thus, it can be presumed that the 
drug permeation into the ocular tissue follows both corneal and non-corneal route. Due to the 
depot formation in conjunctiva, there is controlled and simultaneous drug release from the 
NLC into cornea and sclera since the tissue is in direct contact with cornea and sclera. The 
drug concentration in sclera and RC were calculated to be approximately 3.93 and 2.37-folds 
compared to control subconjunctival injection. Compared to the topical in situ gel, drug 
concentration in the ocular tissues for subconjunctival formulations were 3.0, 4.23, 1.88, 
14.63 and 76.87 folds for VH, cornea, IC, RC and sclera respectively. The superlative levels 
of drug content in all the tissues shows the high-caliber for subconjunctival administration 
compared to topical administration. However, compared to posterior section, the amount of 
drug in the anterior section of the eye was considerably low. This was suggesting that the 
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drug flow route is notably towards the posterior end of the eye. Drug concentration were also 
analyzed in the conjunctival tissue post 6 h of study. The amount of the drug in conjunctiva 
was found to be 31 µg/mL (with the average weight of tissue of 107 mg). Thus, a higher drug 
level in the posterior section of the ocular tissues even after 6 h post injection suggest the 
extended release rates of the drug from the in situ gel system there by proving the 
translational ability of these formulation to clinics.[1], [19] 
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CHAPTER IV 
CONCLUSION 
 
In this study, fluocinolone acetonide NLC in situ gels were successfully formulated 
with vitamin A as one of the lipid by hot homogenization coupled with probe sonication 
method. The formulation had excellent particle size distribution (159) and PDI (0.150). The 
assay and drug entrapment were more than 94% with excellent stability for the period of up 
to four weeks. The stable in situ gel formulated with gellan gum and HPMC showed higher in 
vitro tissue permeation and high drug concentration at posterior end of the ocular tissues 
when administered as subconjunctival injection. Thus exhibiting suitability of these carrier 
systems for prolong ocular pharmacotherapy.  
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